Health care products giant Johnson & Johnson on Wednesday saw its rating and price target boosted by analysts at Goldman Sachs. The firm said it upgraded JNJ from "Neutral" to "Buy" and raised its price target from from $64 to $77
“After two years of earnings and stock underperformance, JNJ may now be on the cusp of an accelerating earnings trajectory, driven by an emerging new product cycle in Pharma, signs of stabilization in MD&D, and a bottoming out in Consumer.”
Aucun commentaire:
Enregistrer un commentaire